The development of prophylactic vaccines against pathogenic bacteria is a major objective of the World Health Organisation. However, vaccine development is often hindered by antigenic diversity and the difficulties encountered manufacturing immunogenic membrane proteins. Here, we employed structure-based design as a strategy to develop Chimeric Antigens (ChAs) for subunit vaccines. ChAs were generated against serogroup B Neisseria meningitidis (MenB), the predominant cause of meningococcal disease in the Western hemisphere. MenB ChAs exploit the lipoprotein factor H binding protein (fHbp) as a molecular scaffold to display the immunogenic VR2 epitope from the integral membrane protein PorA. Structural analyses demonstrate fHbp is correctly folded and that PorA VR2 epitope adopts an immunogenic conformation. In mice, ChAs elicit antibodies directed against fHbp and PorA, with antibody responses correlating to protection against meningococcal disease. ChAs offer a novel approach for generating multivalent subunit vaccines, containing of epitopes from integral membrane proteins, whose composition can be selected to circumvent pathogen diversity.
Introduction
Toxoid and capsule-based vaccines have saved millions of lives caused by bacterial pathogens (Andre, Booy et al., 2008) . For example, toxoid based vaccines have virtually eliminated diphtheria and tetanus in wealthy countries (Arístegui, Usonis et al., 2003 , Schmitt, von Kries et al., 2001 ), while capsule-based vaccines have significantly reduced disease caused by Haemophilus influenza (Murphy, 2015) , Streptococcus pneumonia (Keller, Robinson et al., 2016) , and certain strains of Neisseria meningitidis (Maiden, 2013) .
However, significant challenges remain in developing vaccines against pathogens for which toxoid and capsule-based vaccines are not viable. These pathogens include non-typeable strains of H. influenza and S. pneumonia (Keller et al., 2016 , Murphy, 2015 , unencapsuated pathogens such as Neisseria gonorrhoeae and Moraella catarrhalis (HPA, 2013 , HPA, 2016 , Jerse, Bash et al., 2014 , Schaller, Troller et al., 2006 and encapsulated serogroup B N. meningitidis, for which a capsule based vaccine is not feasible (Finne, Leinonen et al., 1983) . Given the exponential rise in the emergence of multi-drug resistant bacteria (WHO, 2014 , Wi, Lahra et al., 2017 , new approaches for vaccine development are paramount. However, strategies for generating successful vaccines are hampered by pathogen diversity (Telford, 2008) and the difficulties associated with presenting epitopes from membrane-embedded surface proteins to the immune system (Carpenter, Beis et al., 2008) .
Two main approaches have been used to develop vaccines against serogroup B N.
meningitidis; outer membrane vesicle vaccines (OMVVs) and recombinant protein subunit vaccines (RPSVs). OMVVs were first developed around thirty years ago (Bjune, Høiby et al., 1991 , O'Hallahan, Lennon et al., 2004 , Sierra, Campa et al., 1991 . The immunodominant antigen in meningococcal OMVVs is PorA (Saukkonen, Leinonen et al., 1989) , an abundant outer-membrane porin with eight surface-exposed loops (Blake & Gotschilch, 1987 , Judd, 1989 . Loops one and four are termed Variable Region 1 and 2 (VR1 and VR2), respectively, as they elicit immune responses and are subject to antigenic variation (McGuinness, Barlow et al., 1990 , van der Ley, Heckels et al., 1991 . The VR2 loop dominates PorA-specific immunity elicited by OMVVs, which offer limited or no cross-protection against strains expressing PorA with a different VR2 (Holst, Martin et al., 2009 , Martin, Ruijne et al., 2006 , Michaelsen, Ihle et al., 2003 . To broaden coverage, OMVVs have been developed containing multiple PorAs (Claassen, Meylis et al., 1996 , van den Dobbelsteen, van Dijken et al., 2004 , van der Ley, van der Biezen et al., 1995 , selected for their prevalence in circulating strains (Luijkx, van Dijken et al., 2003 , van den Dobbelsteen et al., 2004 .
However, OMVVs present complex manufacturing and regulatory issues (Ulmer, Valley et al., 2006) . More recently, RPSVs Bexsero and Trumenba were developed. These contain the key meningococcal antigen factor H binding protein (fHbp), a lipoprotein composed of two β-barrels that tightly bind domains 6 and 7 of human complement Factor H (CFH) (Madico, Welsch et al., 2006 , Pizza, Scarlato et al., 2000 , Schneider, Exley et al., 2006 , Schneider, Prosser et al., 2009 . fHbp is antigenically variable; public databases contain over 900 different fHbp variants (Jolley & Maiden, Jolley & Maiden, 2010) , which fall into three variant groups or two subfamilies: V1 (subfamily B), V2 and V3 (both subfamily A) (Brehony, Wilson et al., 2009 , Murphy, Andrew et al., 2009 . In general, immunisation with a particular fHbp induces cross-protection against strains expressing fHbp belonging to the same, but not a different, variant group; although there is significant cross-protection between variant groups 2 and 3 (subfamily A) fHbps (Fletcher, Bernfield et al., 2004 , Masignani, Comanducci et al., 2003 . Bexsero contains a single fHbp variant (V1.1), with two other recombinant antigens as well as an OMV (Serruto, Bottomley et al., 2012) , whilst
Trumenba is solely composed of two fHbp variants (V1.55 and V3.45) (Green, Eiden et al., 2016) . Antigens in Bexsero and Trumenba have exact sequence matches to only 36% and 4.8% of serogroup B N. meningitidis disease isolates currently circulating in the UK, respectively (Brehony, Hill et al., 2015, Jolley & Maiden) , leading to concerns about their ability to provide broad coverage against an antigenically diverse pathogen.
We employed a structure-based approach to generate Chimeric Antigens (ChAs) against serogroup B N. meningitidis. ChAs exploit fHbp as a molecular scaffold to present the surface exposed PorA VR2 loop, which is achieved by inserting the VR2 loop into a β-turn region in fHbp. ChAs retain epitopes from both fHbp and PorA, and can elicit functional immune responses against both antigens. We demonstrate integration of a VR2 loop does not alter the overall architecture of fHbp and that the VR2 loop folds into a conformation recognized by a bactericidal mAb. We provide proof-in-principle that ChAs can be used to display selected epitopes from integral membrane proteins, such as PorA. ChAs incorporate epitopes from multiple antigens into a single vaccine antigen, which can be selected to circumvent pathogen antigenic diversity. Furthermore, ChAs contain epitopes from integral membrane proteins, which have previously hindered vaccine development, owing to the difficulties encountered during manufacture.
Results

Design and construction of chimeric fHbp:PorAs
Immunisation with N. meningitidis proteins fHbp and PorA elicits bactericidal antibody responses, which provide a correlate of protection against meningococcal disease (Green et al., 2016 , Serruto et al., 2012 (Figure 1A) . fHbp is a lipoprotein that expresses as a soluble protein in Escherichia coli following removal of the N-terminal lipobox motif (Masignani et al., 2003 Table S1 ). The ChAs all express to high levels in E. coli and were purified by nickel affinity chromatography. Western blot analyses confirm all ChAs retain epitopes recognised by an α-P1.16 mAb and α-fHbp pAbs ( Figure 1C ).
fHbp:PorAs are stable and can bind CFH
Stability of an antigen is an important property of a vaccine, and insertion of PorA epitopes might disrupt the overall structure of the ChA scaffold. Therefore, we determined the thermal stability of ChAs by differential scanning calorimetry (DSC, Table 1 ). Insertion of a PorA loop into the N-or C-terminal β-barrel of fHbp decreased the thermal stability of that β-barrel by 1.0°C to 15.5°C, with little or no effect on the other β-barrel. Overall, the lowest measured melting temperature (T m ) of any β-barrel was 60.5°C, which is considerably higher than the N-terminal T m of V3.45 (41°C), one of the fHbps in Trumenba® (Table 1) .
A key property of fHbp is its ability to bind CFH (Madico et al., 2006 , Schneider et al., 2006 , Schneider et al., 2009 (Figure S1A ). Therefore, surface plasmon resonance (SPR) was used to determine the affinity of each ChA for domains 6 and 7 of CFH ( Figure   S1B ), potentially inhibiting CFH binding.
fHbp:PorA ChAs elicit protective immune responses
To examine the ability of ChAs to elicit immune responses, groups of CD1 mice were immunized with ChAs using alum or monophospholipid A (MPLA) as the adjuvant ( Figure   2A ( Figure 2C and 2E), these antisera did not have PorA-dependent SBA titres.
To activate the classical pathway, bound immunoglobulin (Ig) must recruit the C1q subunit of C1 (Frank, Joiner et al., 1987) . The ability of Ig classes to bind C1q varies; a single IgM can be sufficient for C1q recruitment (Poon, Phillips et al., 1985) , while several IgGs must be bound in close proximity and in a particular conformation (Burton, 1990 , Hughes-Jones & Gardner, 1979 , Sledge & Bing, 1973 Figure 3G ).
Interestingly, there was no detectable IgG1 binding to PorA using sera raised against fHbp V1.1
:PorA 309/P1.16 /MPLA, against which two mice had α-PorA SBA titres ( Figure 3C) ; instead the sera contained significant levels of α-PorA IgG2a and IgM (p≤0.01, Figure 3G ).
ChAs retain the architecture of the fHbp scaffold and PorA loop
To further characterise the fHbp:PorA ChAs, we determined the atomic structures of the P1.16 VR2 loop in residues 151, 294, and 309 of a V1 fHbp, all of which generated SBA titres. The structures were solved using molecular replacement to resolutions of 2.9 Å for loops in the ChAs adopt a conformation that can induce bactericidal antibody responses (Oomen, Hoogerhout et al., 2003 , Oomen, Hoogerhout et al., 2005 .
ChAs containing an expanded range of PorA VR2 loops generate immune responses
To test the adaptability of our fHbp:PorA ChAs, we generated several ChAs composed from different combinations of fHbp and PorA VR2. The comprehensive meningococcal genome data available for strains isolated in the UK enables construction of ChAs that have exact sequence matches to the most common antigens in a given region. In 2016, the most prevalent PorA VR2s in serogroup B N. meningitidis isolates were P1.4 (15.2 %), P1.14 (15.2 %), P1.9 (12.8 %), P1.16 (11.1 %) and P1.15 (5.8 %, Figure 4C ). Whilst the most Table 2) .
Discussion
During infection pathogens present our immune system with an assortment of surface exposed lipid anchored and integral membrane proteins, both of which can be used as components in subunit vaccines. Whilst lipoproteins can be simply engineered for recombinant expression (by removal of their lipid anchor), integral membrane proteins present several challenges for vaccine development. Recombinant forms of integral membrane proteins are often poorly expressed and their native conformations may be compromised during purification, potentially reducing their ability to elicit immune responses against conformational epitopes, such as those found in surface loops (Bagal, Brown et al., 2013 , Carpenter et al., 2008 . Furthermore, immunisation with integral membrane proteins can generate irrelevant immune responses, which are directed towards epitopes masked by the outer membrane (Zhu, Thomas et al., 2005) . To circumvent these issues, we used structure-based design to develop ChAs. We selected a key surface exposed epitope (VR2) from the integral membrane protein PorA and inserted it into the immunogenic scaffold of the lipoprotein fHbp. Multivalent ChAs generate immune responses against two key surface antigens that can elicit protective immunity (Claassen et al., 1996 , Green et al., 2016 , Kaaijk, van Straaten et al., 2013 , Serruto et al., 2012 , providing proof in principle that immunogenic epitopes from integral membrane proteins can be introduced into soluble molecular scaffolds to create ChAs.
Combining two antigens within a single recombinant ChA could diminish the immunogenicity of one or both antigens. We found that fHbp in all ChAs is highly immunogenic, inducing significant bactericidal antibody responses, with titres in excess of those correlated with protection (Andrews et al., 2003) . In addition, the PorA VR2 loop in ChAs can induce antibody responses even when presented away from its native environment in the outer membrane. While all ChAs induced antibodies that detect PorA on the surface of N.
meningitidis, not all induced bactericidal PorA antibodies. We observed a mixed bactericidal PorA response, which depended on the PorA VR2 variant, the position of PorA VR2 in the fHbp scaffold and the adjuvant used for immunisation, indicating that several parameters are crucial for obtaining bactericidal responses.
Linear PorA VR2 P1.16 peptides elicit antibodies that fail to recognise the native protein and are non-bactericidal, while cyclic PorA VR2 peptides, with identical residues but fixed into a β-turn, can elicit antibodies that recognise native PorA and are bactericidal (Christodoulides, McGuinness et al., 1993 , Christodoulides, Rattue et al., 1999 , Hoogerhout, Donders et al., 1995 , Oomen et al., 2003 , Oomen et al., 2005 . Structural data shows that when the structure of cyclic VR2 peptide mirrors that of a linear peptide bound by a bactericidal mAb, and thus locked into an immunogenic conformation, the cyclic peptide induces bactericidal responses (Oomen et al., 2003 , Oomen et al., 2005 . In ChAs, the N-and C-termini of the VR2 loop are bound by neighbouring fHbp β-strands, fixing the VR2 epitope into a β-turn, as observed in cyclic peptides. This was confirmed by the atomic structures of ChAs, in which the PorA adopts the same conformation as when bound by a bactericidal Fab fragment (van den Elsen et al., 1997) . In previous work, cyclic peptides were coupled to carrier proteins and used with adjuvants not licensed for human use (Christodoulides et al., 1993 , Christodoulides et al., 1999 , Oomen et al., 2003 , Oomen et al., 2005 . In the resulting SBAs, titres were only observed with antisera from some mice (Oomen et al., 2005) , similar to our findings with ChAs and licensed adjuvants. (Green et al., 2016 , Serruto et al., 2012 .
Materials and Methods
Bacterial strains and growth
The bacterial strains used in this study are shown in Table S2 and Table S3 . N.
meningitidis was grown in the presence of 5% CO 2 at 37°C on Brain Heart Infusion (BHI, Oxoid, Basingstoke, United Kingdom) plates with 5% (v/v) horse serum (Oxoid) at 37°C.
Escherichia coli was grown on Luria-Bertani (LB) agar plates or LB liquid at 37°C
supplemented with 100 μg μl -1 carbenicillin.
Expression and purification of fHbp-PorAs
N-terminally truncated V1.1 fHbp was amplified from MC58 genomic DNA using primers fHbp F1 and fHbp R4 ( Table S4 ). The PorA P1.16 VR2 (YYTKDTNNNLTLV) was introduced into one of six positions in fhbp by overlap PCR using the primers in Table S4 . The PorA VR2 loops P1.4 (HVVVNNKVATHVP), P1.9 (YVDEQSKYHA), P1.10_1 (HFVQNKQNQPPTLVP), P1.14 (YVDEKKMVHA) and P1.15 (HYTRQNNADVFVP) were introduced into a single position in fHbp by overlap PCR using the primers in Table S4 . PCR products were digested with overnight at 4°C into 50 mM Na-Acetate pH 5.5 buffer and further purification was achieved by ion exchange chromatography (HiTrapSP HP, GE Healthcare) at room temperature with a 0-1 M NaCl gradient in 50 mM Na-Acetate pH 5.5 buffer, followed by gel filtration using a HiLoad 16/600 Superdex 75 pg (GE Healthcare) column equilibrated with phosphate buffered saline (PBS, Oxoid).
Generation of N. meningitidis strains
Deletion of porA was performed by replacing the open reading frame with a tetracyline resistance cassette. Briefly, ~500 bp of the up-and downstream regions of the porA locus flanking a tetracycline resistance cassette was generated by PCR using primers PorA KO: F1, R1, F2, R2 (Table S4 ) and the mega-primer method (Ke & Madison, 1997) . The PCR product was transformed into N. meningitidis H44/76 and H44/76∆fHbp as described previously (Exley, Shaw et al., 2005) . Genomic DNA was obtained (Wizard® genomic DNA purification kit) from the resulting strains and both mutations were backcrossed into the WT H44/76 background using genomic DNA (Exley et al., 2005) .
Western blot analyses
Western blots of purified proteins (0. 
Generation of immune sera
Immunisations were performed with each fHbp:PorA ChA and PBS controls, using alum or All sera were stored at -80°C until required and once defrosted sera were stored at 4°C.
Serum Bactericidal Assays
SBAs were performed as previously described (Jongerius et al., 2013) , with the following modifications. N. meningitidis was suspended in Dubecco's PBS with cations (Gibco) supplemented with 0.1 % glucose (DPBS-G) to a final concentration of 1.25 x 10 4 CFU ml -1 .
Baby rabbit complement (Cedar lane, lot #15027680) was diluted with DPBS-G to a final dilution of 1 in 10. Serum, pooled or from individual mice, was heat inactivated for one hour at 56°C and added to the wells in a serial two-fold dilution, starting with a dilution of 1 in 5 or higher. Control wells contained no serum or no complement. Following static incubation for one hour at 37°C in the presence of 5% CO 2 , 10 µl from each well was plated onto BHI plates in triplicate and colonies from surviving bacteria counted. The bactericidal activity is expressed as the dilution of serum required to kill ≥ 50% of bacteria in assays containing both complement and serum in comparison with control assays containing serum or complement alone. SBAs using pooled sera were repeated three times, and assays using sera from individual mice were repeated twice. SBA titres were input into GraphPad Prism and statistical analyses comparing titres obtained from alum immunisations with titres obtained from MPLA immunisations were performed using two-way ANOVA (statistical significance of p ≤ 0.05) and Dunnett's method of multiple comparisons.
Surface Plasmon Resonance
SPR was performed using a Biacore 3000 (GE Healthcare). Recombinant ChAs were dissolved in 50 mM sodium acetate pH 4.5 and immobilized on a CM5 sensor chip (GE Healthcare). Increasing concentrations of human complement FH domains 6 and 7 (1 nM-16 nM) were injected over the flow channels at 40 µl min 
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V3.45 P1.14 1/640 α-PorA SBA titres generated using pooled ChA/alum antisera and serogroup B N. meningitidis isolates with mismatched fHbp variants. * fHbp truncated at residue 242. and fHbp V3.45 :PorA 158/P1.9 . Figure S1 . Structural alignments of fHbp:PorA ChAs with fHbp and PorA VR2 peptide. Comparison of the geometric means from these histograms, and the histograms from two other independent repeats, is shown in Figures 2C and 2D 
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